Breast Cancer

Evidence that surveillance by mammogram in breast cancer survivors has been lacking until now

Iniparib remains an intriguing therapeutic possibility despite failing to meet its phase III primary endpoints

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Tamoxifen, a common drug used to treat breast cancer, works by blocking the effect of estrogen on tumor cells.

New research suggested that concern about pain may deter obese women from undergoing mammography, while a busy schedule may dissuade women aged less than 60 years

Editors' picks for this month's best Websites, news, resources, and online information for oncologists.

About 40% of insured women in the United States are not undergoing screening mammography at least every 2 years in keeping with guidelines from the USPSTF.

As the Avastin (bevacizumab) drama continues at the FDA, the National Comprehensive Cancer Network (NCCN) has weighed in.

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.

CYP2D6 phenotype status does not predict tamoxifen efficacy in patients with early-stage breast cancer, according to a retrospective analysis of data from the Breast International Group

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.

Debu Tripathy, MD, Co-leader Women’s Breast Cancer Program at USC/Norris Comprehensive Cancer Center, discusses clinical research and studies looking at the use of bisphosphonate for women with breast cancer.

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Breast Cancer's Surgical Progression in the Past 10 Years

Daniel A. Osman, MD, Founder and Course Director of the Miami Breast Cancer Conference Discusses Methods for Detecting Malignant Conditions in Breast Cancer

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Struggles Facing Breast Oncologists

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Genomics and Personalized Medicine

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on his Role in Designing new Equipment

Breast pain is among the most common reasons that women seek medical attention from a breast specialist.